GIBSON DUNN

Gibson Dunn Advises Korsana Biosciences on Merger with Cyclerion Therapeutics

Firm News | April 7, 2026

Gibson Dunn is advising Korsana Biosciences on its merger with Cyclerion Therapeutics, Inc. and concurrent $380 million financing.

The firm's corporate team includes partners Ryan Murr and Branden Berns and associate Evan Shepherd.

Related People

Ryan A. Murr

Branden C. Berns

Evan Shepherd

Related Capabilities

Life Sciences

Mergers and Acquisitions

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**